LINCRNA-P21 AND USE THEREOF

Provided is a composition for treating cancer comprising a DDB2 inhibitor and a chemotherapeutic agent, in which the DDB2 inhibitor comprises three RNA fragments from lincRNA-p21. In addition, the DDB2 inhibitor enhances the chemosensitivity of the cancer to the chemotherapeutic agent for treating cancers that do not respond to chemotherapy..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 08. Feb. Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

HUANG WEI-CHIEN [VerfasserIn]
HE YU-HAO [VerfasserIn]
WEI YA-LING [VerfasserIn]
YAO CHUN-HSU [VerfasserIn]
CHO DER-YANG [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
bio
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-02-08, Last update posted on www.tib.eu: 2024-02-28, Last updated: 2024-03-08

Patentnummer:

WO2024027547

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA019285183